- Home
- NCZ vs TVRD Comparison
NCZ vs TVRD Comparison
Compare NCZ & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCZ
- TVRD
- Stock Information
- Founded
- NCZ 2003
- TVRD 2017
- Country
- NCZ United States
- TVRD United States
- Employees
- NCZ N/A
- TVRD N/A
- Industry
- NCZ Finance Companies
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- NCZ Finance
- TVRD Health Care
- Exchange
- NCZ Nasdaq
- TVRD Nasdaq
- Market Cap
- NCZ 228.3M
- TVRD 246.5M
- IPO Year
- NCZ N/A
- TVRD N/A
- Fundamental
- Price
- NCZ $13.84
- TVRD $33.76
- Analyst Decision
- NCZ
- TVRD Strong Buy
- Analyst Count
- NCZ 0
- TVRD 5
- Target Price
- NCZ N/A
- TVRD $59.20
- AVG Volume (30 Days)
- NCZ 533.0K
- TVRD 22.1K
- Earning Date
- NCZ 01-01-0001
- TVRD 08-14-2025
- Dividend Yield
- NCZ 12.16%
- TVRD N/A
- EPS Growth
- NCZ N/A
- TVRD N/A
- EPS
- NCZ N/A
- TVRD N/A
- Revenue
- NCZ N/A
- TVRD N/A
- Revenue This Year
- NCZ N/A
- TVRD N/A
- Revenue Next Year
- NCZ N/A
- TVRD N/A
- P/E Ratio
- NCZ N/A
- TVRD N/A
- Revenue Growth
- NCZ N/A
- TVRD N/A
- 52 Week Low
- NCZ $2.50
- TVRD $8.13
- 52 Week High
- NCZ $3.15
- TVRD $36.71
- Technical
- Relative Strength Index (RSI)
- NCZ 70.85
- TVRD 65.62
- Support Level
- NCZ $13.70
- TVRD $29.33
- Resistance Level
- NCZ $13.94
- TVRD $36.71
- Average True Range (ATR)
- NCZ 0.09
- TVRD 2.02
- MACD
- NCZ 0.02
- TVRD 0.43
- Stochastic Oscillator
- NCZ 83.05
- TVRD 65.64
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.